The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study

Narongkorn Saiphoklang, Pimchanok Patanayindee, and Pitchayapa Ruchiwit

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Bangkok, Thailand

Correspondence should be addressed to Narongkorn Saiphoklang; m_narongkorn@hotmail.com

Received 24 May 2022; Accepted 16 September 2022; Published 26 September 2022

Academic Editor: Samuel A. Tisherman

Copyright © 2022 Narongkorn Saiphoklang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Lung fibrosis is a sequela of COVID-19 among patients with severe pneumonia. Idiopathic pulmonary fibrosis and lung fibrosis due to COVID-19 may share many similar features. There are limited data on effects of antifibrotic treatment of infection-related lung fibrosis. This study aimed to evaluate the effect of nintedanib on patients’ post-COVID-19 lung fibrosis.

Methods. A retrospective, matched case-control study was performed on hospitalized patients with COVID-19 pneumonia. Patients who received nintedanib treatment for COVID-19 pulmonary fibrosis (nintedanib group) were compared to patients with standard treatment (control group). The primary outcome was oxygen improvement. The secondary outcomes were chest X-ray improvement, SpO2/FiO2 ratio improvement, mortality rates at 60 days, and adverse events.

Results. A total of 42 patients with COVID-19 pneumonia were included (21 in each group). Mean age was 64.43 ± 14.59 years, and 54.8% were men. At baseline, SpO2/FiO2 ratio before treatment was 200.57 ± 105.77 in the nintedanib group and 326.90 ± 137.10 in the control group (P = 0.002). Oxygen improvement and chest X-ray improvement were found in 71.4% and 71.4% in the nintedanib group and in 66.7% and 66.7% in the control group (P = 0.739). The nintedanib group had more improvement in SpO2/FiO2 ratio than in the control group (144.38 ± 118.05 vs 55.67 ± 75.09, P = 0.006). The 60-day mortality rates of the nintedanib and the control groups were 38.1% vs 23.8%, P = 0.317. Hepatitis and loss of appetite were common adverse events (9.5% and 9.5%), while the incidence of diarrhea was 4.8%. Conclusions. Nintedanib as add-on treatment in post-COVID-19 lung fibrosis did not improve oxygenation, chest X-ray findings, or the 60-day mortality. However, this antifibrotic drug improved SpO2/FiO2 ratio in our patients. Further randomized controlled trials are needed to determine the efficacy of nintedanib for treatment of patients with post-COVID-19 lung fibrosis. Trial Registration. This study was registered in TCTR20220426001.

1. Introduction

Coronavirus disease 2019 (COVID-19) was first discovered in Wuhan, Hubei Province, China, in late 2019 [1]. The symptoms of COVID-19 infection vary, ranging from mild upper respiratory tract symptoms to severe acute respiratory distress syndrome [2]. With the development of better treatments, the COVID-19 survival rate has improved. However, many patients experience long-term post-COVID-19 sequelae, such as respiratory problems, decreased exercise tolerance, and lung damage [3, 4]. Pulmonary fibrosis is a consequence of COVID-19 infection and the basis for poor prognosis in COVID-19 patients [5, 6]. The mechanism of pulmonary fibrosis occurs after lung injury caused by stimuli such as viral inflammation or ventilator-induced lung injury, stimulating the function of fibroblasts via inflammatory markers such as transforming growth factor β and interleukin-6, leading to the accumulation of collagen and pulmonary fibrosis [5, 7–9]. The prevalence of post-COVID-19 fibrosis varies from 2% to 45%, depending on the severity of the virus [10–12]. The condition usually occurs in the third week of illness [11]. 10% of patients still have pulmonary fibrosis nine months after the illness [10]. Some are still tired after exertion and need oxygen support, limiting their quality of life [10, 13]. Factors associated with pulmonary fibrosis in COVID-19 patients...
include age, severity of disease, duration of mechanical ventilation and intensive care, smoking, and drinking alcohol [6].

Nintedanib is a tyrosine kinase inhibitor against growth factor receptors with intrinsic tyrosine kinase activity [14]. Nintedanib is an antifibrotic drug approved for the treatment of idiopathic pulmonary fibrosis (IPF) and autoimmune-related lung fibrosis, e.g., systemic sclerosis-associated ILD (SSc-ILD) [15–18]. This medication can slow the IPF progression measured by decline in forced vital capacity (FVC) [19, 20]. It has been approved for the treatment of other progressive fibrosing interstitial lung diseases (PF-ILD) [21, 22]. Interestingly, the combination of two antifibrotic drugs (nintedanib and pirfenidone) is proposed to enhance the therapeutic benefit by simultaneously acting on two different pathogenic pathways [23]. Combined nintedanib and pirfenidone treatment is superior to nintedanib monotherapy in terms of slower FVC decline in IPF [24]. There are few studies on using nintedanib as a treatment for pulmonary fibrosis caused by COVID-19 infections [25–27]. It may have a role in preventing severe lung fibrosis after SARS-CoV-2 infection, especially in patients with the PF-ILD phenotype [23].

There are limited data on nintedanib for treatment of post-COVID-19 pulmonary fibrosis. This study aimed to determine the effects of nintedanib in patients with COVID-19 lung fibrosis.

2. Materials and Methods

2.1. Study Design and Participants. We conducted a retrospective, matched case-control study with medical chart review of adult patients diagnosed with COVID-19 between January 2021 and January 2022 at Thammasat University Hospital, Thailand. We included hospitalized patients aged 18 years or older with laboratory-confirmed COVID-19 infection by polymerase chain reaction of nasopharyngeal swab or other respiratory samples. All participants had to be diagnosed with pneumonia, which was confirmed by chest radiographs. Pulmonary fibrosis was defined as the presence of reticulation, interlobular septal thickening, traction bronchiectasis, or honeycombing on a chest computed tomography (CT) scan report by a thoracic radiologist. We excluded patients with mild disease, defined as normal chest radiographs and oxygen saturation level (oxygen saturation 95% or higher).

The study was approved by the Human Research Ethics Committee of Thammasat University (Medicine), Thailand (Project No. MTU-EC-1M-0-292/64, Certificate of Approval No.004/2022), in compliance with the Declaration of Helsinki, the Belmont Report, CIOMS Guidelines, and the International Conference on Harmonization-Good Clinical Practice (ICH-GCP). Written informed consent was waived because this study was a retrospective study.

2.2. Procedures. Patients who received nintedanib were included in the study as the nintedanib group. Patients with standard treatments were included as the control group. Standard treatments according to local COVID-19 guidelines included antiviral agents (favipiravir or remdesivir), corticosteroids (methylprednisolone or dexamethasone), antibiotics (e.g., amoxicillin/clavulanate, ceftriaxone, and levofloxacin), anticoagulants (enoxaparin or unfractionated heparin), and immunomodulatory agents (tocilizumab or baricitinib). The nintedanib and control groups were matched by age, comorbidities, and time from symptom onset to the administration of antifibrotic agent. Nintedanib was used at 150 mg twice daily. The duration of administration depended on the physician in charge.

Clinical data including demographic characteristics, comorbidities, clinical characteristics (symptoms at initial presentation, date of pneumonia diagnosis, and CT finding), laboratory test results (complete blood count, absolute lymphocyte count, liver function test, serum creatinine, and C-reactive protein), oxygen status, oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) ratio, and chest X-ray findings before and after treatment, duration of hospitalization, adverse effects of antifibrotic treatment, and status at 60-day after admission were retrieved from electronic medical records.

2.3. Study Outcomes. The primary endpoint was oxygen improvement, which was defined as oxygen support decreased from high-flow to low-flow oxygen devices or 3% increase of SpO2 detected by the same pulse oximeter. The secondary endpoints were 10% improvement in chest X-ray between before and after treatment as determined by the thoracic radiologist, adverse events, difference in SpO2/FiO2 ratio between before and after treatment, length of hospital stay, and status (alive or dead) at 60 days after admission.

2.4. Statistical Analysis. We hypothesized that oxygen improvement in the nintedanib and control groups was 50% and 10%, respectively. The sample size would be 40 (20 per group) using 80% power and 5% type I error.

Data are expressed as number (%) and mean ± standard deviation. The chi-squared test was used to compare categorical variables between two groups. Student’s t-test was used to compare continuous variables between two groups. Two-tailed P values of less than 0.05 were considered statistically significant. All data analyses were done on SPSS version 26.0 software (IBM Corp., Armonk, NY, USA).

3. Results

A total of 4,489 COVID-19 patients were screened. Of these, 829 patients had COVID-19 pneumonia requiring hospitalization and 44 patients (21 in each group) were included in the study (Figure 1). Mean age was 64.43 ± 14.59 years. 54.8% were male, and 11.9% were smokers. Common comorbidities included hypertension (64.3%), diabetes (50.0%), and dyslipidemia (42.9%). Cough (85.7%) was the most common symptom, followed by fever (78.6%) and breathlessness (40.5%). Baseline characteristics, laboratory results, oxygen status, and standard COVID-19 treatment were not significantly different between two groups except...
SpO$_2$/FiO$_2$ ratio and oxygen therapy before antifibrotic or standard treatment (Table 1). Mean duration of antifibrotic treatment was 17.86 ± 10.89 days (Table 2). Mean length of hospital stay in the nintedanib group was 35.48 ± 15.92 days (Table 2).

The nintedanib group improved significantly more in SpO$_2$/FiO$_2$ ratio after treatment than the control group (mean difference in 88.71, P = 0.006) (Table 2 and Figure 2). There were no significant differences in length of hospital stay, oxygen or chest X-ray improvement, or mortality rates at 60 days after first admission between two groups (Table 2). Mortality rates at 60 days in the nintedanib group and in the control group were 38.1% and 23.8%, respectively (P = 0.317) (Table 2).

Nintedanib side effects were hepatitis (9.5%), loss of appetite (9.5%), and diarrhea (4.8%) (Table 2). Three patients (14.3%) in the nintedanib group discontinued the medication due to hepatitis or diarrhea. No adverse effect was reported in the control group (Table 2).

4. Discussion

This is the first study to evaluate the effect of nintedanib in post-COVID-19 pulmonary fibrosis in Thailand. Nintedanib improved SpO$_2$/FiO$_2$ ratio. However, there were no differences in chest X-ray or oxygen improvement between the nintedanib and the control group. Baseline SpO$_2$/FiO$_2$ ratio in the nintedanib group was significantly lower than that in the control group, which may explain the greater improvement. The lack of differences in these clinical outcomes may be because of relatively short duration of antifibrotic therapy in our study (17 days). A study by Ogata and colleagues found that after 3 months of antifibrotic treatment for post-COVID-19 lung fibrosis, patients were able to reduce oxygen therapy and had better chest radiographs [25]. A study by Richeldi and coworkers found that continuing nintedanib treatment in IPF for 53 weeks showed decline in lung function, reduced relapse of the disease (acute exacerbation), and reduced the mortality rate [20].

When medication was initiated may be another important factor. Fibrosis in COVID-19 is partly caused by cytokines such as interleukin-1 and interleukin-6 during the inflammatory phase of the disease or caused by injury from mechanical ventilation that stimulates fibroblast malfunction, causing the excessive accumulation of collagen, all of which results in fibrosis [5, 7]. In our study, some patients were in acute inflammatory phase or received mechanical ventilation for treatment of severe pneumonia or acute respiratory distress syndrome, and antifibrotic drug therapy at this stage may not have been as effective as expected.

A study by Umemura and coworkers found that starting nintedanib treatment from the first day of intubation significantly reduced duration of intubation and improved chest CT findings [26].

Our study found that patients in the nintedanib group had higher 60-day mortality than the control group. Lower baseline SpO$_2$/FiO$_2$ ratio in the nintedanib group reflected more severe disease, which explains the higher mortality rate. Our study found that in the nintedanib group, the mean hospital stay was 35 days, similar to a previous study by Wu and coworkers [28]. Long duration of hospital stay was a risk factor for abnormal chest CT scans at 12 months after discharge from hospital [28].

Our study showed chest CT features in patients with post-COVID-19 which were consistent with previous studies (ground glass opacity, consolidation, reticulation, and traction bronchiectasis) [28–30]. A study by Liu and colleagues found that 64.7% of COVID-19 patients had normal chest CT radiographs at 4 weeks after leaving the hospital [30].

Our study found that the most common side effect of nintedanib was transaminitis, with alanine aminotransferase levels greater than 5 times greater at day 10 of treatment, requiring discontinuation of medication. Hepatitis was also found, from COVID-19 itself or from treatment-related conditions [31]. The use of antifibrotic drugs in severely ill patients with COVID-19, especially patients admitted to intensive care units, needs to be monitored more closely. Other common side effects are diarrhea and loss of appetite which are common side effects of antifibrotic drugs for treatment in IPF [20]. These side effects did not result in death in our study.
Table 1: Baseline characteristics of hospitalized patients with COVID-19 pneumonia.

| Variables | Total (n=42) | Nintedanib group (n=21) | Control group (n=21) | P value |
|-----------|--------------|-------------------------|----------------------|---------|
| Age, years | 64.43 ± 14.59 | 61.29 ± 13.76 | 67.57 ± 15.05 | 0.166 |
| Male | 23 (54.8) | 12 (57.1) | 11 (52.4) | 0.096 |
| Body mass index, kg/m² | 27.50 ± 5.80 | 26.48 ± 3.38 | 28.51 ± 7.45 | 0.189 |
| Smoking status | | | | |
| Non-smoker | 37 (88.1) | 17 (80.9) | 20 (95.2) | 0.343 |
| Current or former smoker | 5 (11.9) | 4 (19.0) | 1 (4.8) | 0.343 |
| Comorbidity | | | | |
| Hypertension | 27 (64.3) | 12 (57.1) | 15 (71.4) | 0.334 |
| Diabetes | 21 (50.0) | 10 (47.6) | 11 (52.4) | 0.758 |
| Dyslipidemia | 18 (42.9) | 11 (52.4) | 7 (33.3) | 0.212 |
| Coronary arterial disease | 4 (9.5) | 1 (4.8) | 3 (14.3) | 0.606 |
| Stroke | 2 (4.8) | 1 (4.8) | 1 (4.8) | 1.000 |
| Time from symptom onset to hospitalization, days | 7.50 ± 14.21 | 5.00 ± 2.55 | 10.00 ± 19.86 | 0.259 |
| Time from symptom onset to pneumonia diagnosis, days | 7.28 ± 14.03 | 4.38 ± 2.48 | 10.19 ± 19.49 | 0.183 |
| Admission ward | | | | |
| Intensive care unit | 18 (42.9) | 10 (47.6) | 8 (38.1) | 0.533 |
| Intermediate care unit | 24 (57.1) | 11 (52.4) | 13 (61.9) | 0.533 |
| Symptom | | | | |
| Fever | 33 (78.6) | 19 (90.5) | 14 (66.7) | 0.130 |
| Cough | 36 (85.7) | 17 (80.9) | 19 (90.5) | 0.663 |
| Breathlessness | 17 (40.5) | 10 (47.6) | 7 (33.3) | 0.346 |
| Rhinorrhea | 6 (14.3) | 4 (19.0) | 2 (9.5) | 0.663 |
| Sore throat | 5 (11.9) | 4 (19.0) | 1 (4.8) | 0.343 |
| Headache | 3 (7.1) | 3 (14.3) | 0 (0) | 0.232 |
| Anosmia | 3 (7.1) | 2 (9.5) | 1 (4.8) | 1.000 |
| Chest tightness | 1 (2.4) | 1 (4.8) | 0 (0) | 1.000 |
| Ageusia | 1 (2.4) | 1 (4.8) | 0 (0) | 1.000 |
| Laboratory data | | | | |
| Hemoglobin, g/dL | 12.70 ± 1.79 | 12.85 ± 1.79 | 12.57 ± 1.83 | 0.625 |
| White blood cell count, cells/µL | 7,429.27 ± 3,781.48 | 7,275 ± 4,097.22 | 7,576 ± 3,550.34 | 0.802 |
| Platelet count, 10³/µL | 18.62 ± 11.73 | 18.13 ± 12.57 | 19.09 ± 11.17 | 0.798 |
| Lymphocyte, % | 18.62 ± 11.73 | 18.13 ± 12.57 | 19.09 ± 11.17 | 0.798 |
| Absolute lymphocyte count, cells/µL | 1,080.12 ± 599.17 | 955.41 ± 443.11 | 1198.9 ± 707.89 | 0.193 |
| Creatinine, mg/dL | 1.43 ± 0.50 | 1.37 ± 0.50 | 1.44 ± 0.47 | 0.862 |
| Albumin, g/dL | 3.45 ± 0.50 | 3.47 ± 0.50 | 3.44 ± 0.47 | 0.862 |
| C-reactive protein, mg/L | 78.06 ± 55.86 | 83.6 ± 63.07 | 72.78 ± 49.02 | 0.542 |
| SpO2/FiO2 ratio | | | | |
| Before treatment | 263.73 ± 136.79 | 200.57 ± 105.77 | 326.90 ± 137.10 | 0.002 |
| After treatment | 357.95 ± 148.22 | 335.71 ± 168.12 | 380.19 ± 125.44 | 0.338 |
| Treatment | | | | |
| Favipiravir | 42 (100) | 21 (100) | 21 (100) | 1.000 |
| Remdesivir | 5 (11.9) | 3 (14.3) | 2 (9.5) | 1.000 |
| Antibiotics | 42 (100) | 21 (100) | 21 (100) | 1.000 |
| Corticosteroids | 42 (100) | 21 (100) | 21 (100) | 1.000 |
| Anticoagulant | 42 (100) | 21 (100) | 21 (100) | 1.000 |
| Tocilizumab | 7 (16.7) | 6 (28.6) | 1 (4.8) | 0.093 |
| Baricitinib | 2 (4.8) | 1 (4.8) | 1 (4.8) | 1.000 |
| Oxygen therapy before treatment | | | | |
| No | 10 (23.8) | 2 (9.5) | 8 (38.1) | 0.030 |
| Cannula | 8 (19.0) | 4 (19.0) | 4 (19.0) | 1.000 |
| High-flow nasal cannula | 8 (19.0) | 8 (38.1) | 0 (0) | 0.003 |
| Endotracheal tube with mechanical ventilation | 15 (35.7) | 7 (33.3) | 8 (38.1) | 0.747 |
| Chest CT finding | | | | |
| Ground glass opacity | 36 (85.7) | 17 (81.0) | 19 (90.5) | 0.663 |
| Reticulation | 29 (69.0) | 14 (66.7) | 15 (71.4) | 0.739 |
| Consolidation | 27 (64.3) | 11 (52.4) | 16 (76.2) | 0.107 |
| Traction bronchiectasis | 22 (52.4) | 10 (47.6) | 12 (57.1) | 0.537 |
| Honeycombing | 2 (4.8) | 2 (9.5) | 0 (0) | 0.488 |

Data shown as n (%) or mean ± SD. CT=chest computed tomography; SpO2/FiO2=oxygen saturation to fraction of inspired oxygen.
Table 2: Clinical outcomes of hospitalized patients with COVID-19 pneumonia.

| Variables                                  | Nintedanib group (n=21) | Control group (n=21) | Mean difference (95% CI) | P value |
|--------------------------------------------|--------------------------|----------------------|--------------------------|---------|
| SpO₂/FiO₂ ratio difference between before and after treatment | 144.38 ± 118.05          | 55.67 ± 75.09        | 88.71 (26.66 to 105.76)  | 0.006   |
| Length of hospital stay, days              | 35.48 ± 15.92            | 38.57 ± 18.32        | −3.10 (−13.80 to 7.61)   | 0.562   |
| Oxygen improvement                         | 15 (71.4)                | 14 (66.7)            | NA                       | 0.739   |
| Chest X-ray improvement                    | 15 (71.4)                | 14 (66.7)            | NA                       | 0.739   |
| Mortality at 60 days after first admission | 8 (38.1)                 | 5 (23.8)             | NA                       | 0.317   |
| Duration of antifibrotic treatment, days   | 17.86 ± 10.89            | 0 ± 0                | 17.85 (12.89 to 22.81)   | <0.001  |

Adverse event

| Variable         | Nintedanib (n=21) | Control (n=21) | P value |
|------------------|-------------------|----------------|---------|
| Hepatitis        | 2 (9.5)           | 0 (0)          | 0.488   |
| Loss of appetite | 2 (9.5)           | 0 (0)          | 0.488   |
| Diarrhea         | 1 (4.8)           | 0 (0)          | 1.000   |

Data shown as n (%) or mean ± SD. NA = not applicable; SpO₂/FiO₂ = oxygen saturation to fraction of inspired oxygen.

Figure 2: Oxygen saturation to fraction of inspired oxygen (SpO₂/FiO₂) difference between before and after treatment.

There were a few limitations of our study. Firstly, because this was a retrospective study, information was limited. It was difficult to select patient samples in the control group which had clinical characteristics and severity of disease similar to the nintedanib group. Secondly, a small sample size of the population was used in this study. Thus, study outcomes might not be representative of the whole population and some results might not be obviously different between groups. Lastly, because this was a single-center study, it might not represent the entire population. Randomized control trials with more patients are required to investigate for long-term outcomes in post-COVID-19 lung fibrosis.

5. Conclusions

Nintedanib in COVID-19 patients with pulmonary fibrosis did not improve oxygenation, chest X-ray findings, or 60-day mortality after admission. However, the nintedanib group had a significantly higher SpO₂/FiO₂ ratio difference after treatment than the control group. For future study in antifibrotic therapy for COVID-19 patients, a randomized control trial is needed to select groups of patients who would benefit from antifibrotic treatment. The appropriate timing to start medication should also be investigated for better treatment efficacy.

Data Availability

The data supporting the results of this study are available within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

PP, NS, and PR contributed to the design of this study. PP collected, analyzed, and interpreted the data and drafted this manuscript. NS and PR reviewed the final manuscript. All authors read, approved, and agreed on the final manuscript.
All authors participated in the design of this analysis, data collection and analysis, paper writing, and revision.

Acknowledgments

The authors would like to thank Michael Jan Everts, Faculty of Medicine, Thammasat University, for proofreading this manuscript. This study was supported by the Research Group in Airway Diseases and Allergy, Faculty of Medicine, Thammasat University, Thailand.

References

[1] Z. Wu and J. M. McGoogan, “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China summary of a report of 72314 cases from the Chinese center for disease control and prevention,” JAMA, vol. 323, no. 13, pp. 1239–1242, 2020.
[2] R. B. Aguilar, P. Hardigan, B. Mayi et al., “Current understanding of COVID-19 clinical course and investigational treatments,” Frontiers of Medicine, vol. 7, Article ID 555301, 2020.
[3] V. Higgins, D. Sohaid, E. P. Diamandis, and I. Prassas, “COVID-19: from an acute to chronic disease? Potential long-term health consequences,” Critical Reviews in Clinical Laboratory Sciences, vol. 58, no. 5, pp. 297–310, 2021.
[4] A. Pavli, M. Theodoridou, and H. C. Maltezou, “Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals,” Archives of Medical Research, vol. 52, no. 6, pp. 575–581, 2020.
[5] A. E. John, C. Joseph, G. Jenkins, and A. L. Tatler, “COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts,” Immunological Reviews, vol. 302, no. 1, pp. 228–240, 2021.
[6] A. S. Ojo, S. A. Balogun, O. T. Williams, and O. S. Ojo, “Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies,” Pulmonary Medicine, vol. 2020, Article ID 6175964, 10 pages, 2020.
[7] A. Mohammad, I. Balan, S. Yadv et al., “Post-COVID-19 pulmonary fibrosis,” Careus, vol. 14, no. 3, Article ID e22770, 2022.
[8] C. Zhang, Z. Wu, J. W. Li et al., “Discharge may not be the end of treatment pay attention to pulmonary fibrosis caused by severe COVID-19,” Journal of Medical Virology, vol. 93, no. 3, pp. 1378–1386, 2021.
[9] C. M. Rumende, E. C. Susanto, and T. P. Sitorus, “The management of pulmonary fibrosis in COVID-19,” Acta Med Indones, vol. 53, no. 2, pp. 233–241, 2021.
[10] E. Bazdyrev, P. Rusina, M. Panova, F. Novikov, I. Grishagin, and V. Nebolsin, “Lung fibrosis after COVID-19 treatment prospects,” Pharmaceuticals, vol. 14, p. 807, 2021.
[11] S. B. Polak, I. C. Van Gool, D. Cohen, J. H. von der Thesen, and J. van Paassen, “A systematic review of pathological findings in COVID-19 a pathophysiologic timeline and possible mechanisms of disease progression,” Modern Pathology, vol. 33, no. 11, pp. 2128–2138, 2020.
[12] B. J. Hama Amin, F. H. Kakamad, G. S. Ahmed et al., “Post COVID-19 pulmonary fibrosis: a meta-analysis study,” Annals of Medicine and Surgery, vol. 77, Article ID 103590, 2022.
[13] A. S. Shah, A. W. Wong, C. J. Hague et al., “A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations,” Thorax, vol. 76, no. 4, pp. 402–404, 2021.
[14] L. Wellin, E. Wex, A. Pautsch et al., “Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 45, no. 5, pp. 1434–1445, 2015.
[15] P. Spagnolo, J. A. Kropski, M. G. Jones et al., “Idiopathic pulmonary fibrosis: disease mechanisms and drug development,” Pharmacology and Therapeutics, vol. 222, Article ID 107798, 2021.
[16] E. Bendstrup, W. Wuys, T. Alfaro et al., “Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events,” Respiration, vol. 97, no. 2, pp. 173–184, 2019.
[17] Y. N. Lamb, “Nintedanib: a review in fibrotic interstitial lung diseases,” Drugs, vol. 81, no. 5, pp. 575–586, 2021.
[18] O. Distler, K. B. Highland, M. Gahlemann et al., “Nintedanib for systemic sclerosis-associated interstitial lung disease,” New England Journal of Medicine, vol. 380, no. 26, pp. 2518–2528, 2019.
[19] L. Richeldi, U. Costabel, M. Selman et al., “Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis,” New England Journal of Medicine, vol. 365, no. 12, pp. 1079–1087, 2011.
[20] L. Richeldi, R. M. du Bois, G. Raghu et al., “Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis,” New England Journal of Medicine, vol. 370, no. 22, pp. 2071–2082, 2014.
[21] K. R. Flaherty, A. U. Wells, V. Cottin et al., “Nintedanib in progressive fibrosing interstitial lung diseases,” New England Journal of Medicine, vol. 381, no. 18, pp. 1718–1727, 2019.
[22] A. U. Wells, K. R. Flaherty, and K. K. Brown, “Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial,” Lancet Respiratory Medicine, vol. 8, no. 5, pp. 453–460, 2020.
[23] J. M. Serra Lopez-Mateuncio, M. Gomez, E. F. Vicente-Rabaneda, M. A. Gonzalez-Gay, J. Ancochea, and S. Castaneda, “Pharmacological interactions of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis in times of COVID-19 pandemic,” Pharmaceuticals, vol. 14, p. 819, 2021.
[24] C. Vancheri, M. Kreuter, L. Richeldi et al., “Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial,” American Journal of Respiratory and Critical Care Medicine, vol. 197, no. 3, pp. 356–363, 2018.
[25] H. Ogata, T. Nakagawa, S. Sakoda et al., “Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019,” Respirology Case Reports, vol. 9, no. 5, Article ID e00744, 2021.
[26] Y. Umemura, Y. Mitsuyama, K. Minami et al., “Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: an interventional study,” International Journal of Infectious Diseases, vol. 108, pp. 454–460, 2021.
[27] M. Vikas, R. Choudhary, V. Malik, A. Pemmaraju, and D. Peter, “Early experience of nintedanib in COVID-19 ARDS-related pulmonary fibrosis: a case series,” Advances in Respiratory Medicine, vol. 89, no. 6, pp. 589–596, 2021.
[28] X. Wu, X. Liu, Y. Zhou et al., “3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation a prospective study,” Lancet Respiratory Medicine, vol. 9, no. 7, pp. 747–754, 2021.
[29] C. Huang, L. Huang, Y. Wang et al., “6-month consequences of COVID-19 in patients discharged from hospital: a cohort
study,” The Lancet, vol. 397, pp. 220–232, Article ID 10270, 2021.

[30] C. Liu, L. Ye, R. Xia et al., “Chest computed tomography and clinical follow-up of discharged patients with COVID-19 in Wenzhou City, Zhejiang, China,” Annals of the American Thoracic Society, vol. 17, no. 10, pp. 1231–1237, 2020.

[31] D. A. McGrowder, F. Miller, M. Anderson Cross, L. Anderson-Jackson, S. Bryan, and L. Dilworth, “Abnormal liver biochemistry tests and acute liver injury in COVID-19 patients current evidence and potential pathogenesis,” Diseases, vol. 9, p. 50, 2021.